This is a South Africa news story, published by BGR, that relates primarily to Gilead Sciences news.
For more South Africa news, you can click here:
more South Africa newsFor more drug discoveries news, you can click here:
more drug discoveries newsFor more news from BGR, you can click here:
more news from BGROtherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about
preventative HIV drug. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest moderate injectable preventative HIV drug news, new HIV infections news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!
other HIV blockersBGR
•75% Informative
A recent clinical trial for a preventative HIV drug has come back with shocking effectiveness.
The preventative drug in question is called Lenacapavir and it was tested by a Gilead Sciences team across 25 different sites in South Africa and Uganda .
Over a six-month period, the medication had a 100% success rate when delivered via injection just twice a year.
That's far more effective than two other PrEP drugs that are currently on the market.
VR Score
74
Informative language
75
Neutral language
4
Article tone
semi-formal
Language
English
Language complexity
52
Offensive language
possibly offensive
Hate speech
not hateful
Attention-grabbing headline
not detected
Known propaganda techniques
not detected
Time-value
medium-lived
External references
3
Source diversity
2
Affiliate links
no affiliate links